Regenxbio (RGNX) Cash from Investing Activities (2016 - 2025)
Regenxbio has reported Cash from Investing Activities over the past 11 years, most recently at $37.5 million for Q4 2025.
- Quarterly results put Cash from Investing Activities at $37.5 million for Q4 2025, down 6.79% from a year ago — trailing twelve months through Dec 2025 was -$15.9 million (down 115.34% YoY), and the annual figure for FY2025 was -$15.9 million, down 115.34%.
- Cash from Investing Activities for Q4 2025 was $37.5 million at Regenxbio, down from $42.3 million in the prior quarter.
- Over the last five years, Cash from Investing Activities for RGNX hit a ceiling of $63.1 million in Q1 2023 and a floor of -$216.4 million in Q4 2021.
- Median Cash from Investing Activities over the past 5 years was $30.3 million (2022), compared with a mean of -$7.0 million.
- Biggest five-year swings in Cash from Investing Activities: skyrocketed 5208.05% in 2023 and later plummeted 52301.49% in 2025.
- Regenxbio's Cash from Investing Activities stood at -$216.4 million in 2021, then soared by 112.34% to $26.7 million in 2022, then increased by 27.24% to $34.0 million in 2023, then increased by 18.54% to $40.3 million in 2024, then dropped by 6.79% to $37.5 million in 2025.
- The last three reported values for Cash from Investing Activities were $37.5 million (Q4 2025), $42.3 million (Q3 2025), and -$140.4 million (Q2 2025) per Business Quant data.